

7. The crystalline oxalate salt of Claim 6, wherein the crystalline oxalate salt is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 34.

8. The crystalline oxalate salt of Claim 6, wherein the crystalline oxalate salt is characterized by a melting point in the range of about 162 °C to about 164 °C.

9. The crystalline oxalate salt of Claim 6, wherein the crystalline oxalate salt is characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 45.

10. A pharmaceutical composition comprising:

- (a) a crystalline oxalate salt of any one of Claims 1 to 9; and
- (b) a pharmaceutically-acceptable carrier.

11. A pharmaceutical composition comprising:

- (a) a crystalline oxalate salt of any one of Claims 1 to 9;
- (b) a steroidal anti-inflammatory agent or a pharmaceutically acceptable salt or solvate thereof; and
- (b) a pharmaceutically-acceptable carrier.

12. Use of a crystalline oxalate salt of any one of Claims 1 to 9 in the manufacture of a medicament for treating a pulmonary disorder.

13. Use of (a) a crystalline oxalate salt of any one of Claims 1 to 9; and (b) a steroidal anti-inflammatory agent or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating a pulmonary disorder.

14. The use of Claim 12 or 13, wherein the pulmonary disorder is chronic obstructive pulmonary disease or asthma.